Business Description
Hunan Er-Kang Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100001781
Share Class Description:
SZSE:300267: Class ACompare
Compare
Traded in other countries / regions
300267.China IPO Date
2011-09-27Description
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.51 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -1.67 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 5.43 | |||||
| Beneish M-Score | -3.13 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.2 | |||||
| 3-Year EBITDA Growth Rate | -68.7 | |||||
| 3-Year FCF Growth Rate | 42.7 | |||||
| 3-Year Book Growth Rate | -5.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.29 | |||||
| 9-Day RSI | 67.69 | |||||
| 14-Day RSI | 62.14 | |||||
| 6-1 Month Momentum % | -25.8 | |||||
| 12-1 Month Momentum % | -23.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.78 | |||||
| Quick Ratio | 1.65 | |||||
| Cash Ratio | 0.86 | |||||
| Days Inventory | 233.68 | |||||
| Days Sales Outstanding | 29 | |||||
| Days Payable | 46.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.08 | |||||
| 3-Year Dividend Growth Rate | 44.2 | |||||
| Forward Dividend Yield % | 1.08 | |||||
| 5-Year Yield-on-Cost % | 1.07 | |||||
| Shareholder Yield % | 2.11 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 21.34 | |||||
| Operating Margin % | -7.81 | |||||
| Net Margin % | -14.45 | |||||
| FCF Margin % | 3.13 | |||||
| ROE % | -4.39 | |||||
| ROA % | -3.95 | |||||
| ROIC % | -2.76 | |||||
| ROC (Joel Greenblatt) % | -5.64 | |||||
| ROCE % | -4.21 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 23.17 | |||||
| PS Ratio | 3.76 | |||||
| PB Ratio | 1.19 | |||||
| Price-to-Tangible-Book | 1.29 | |||||
| Price-to-Free-Cash-Flow | 115.85 | |||||
| Price-to-Operating-Cash-Flow | 20.27 | |||||
| EV-to-EBIT | -26.51 | |||||
| EV-to-EBITDA | -26.51 | |||||
| EV-to-Revenue | 3.71 | |||||
| EV-to-FCF | 108.34 | |||||
| Price-to-Projected-FCF | 2.03 | |||||
| Price-to-Median-PS-Value | 0.92 | |||||
| Price-to-Net-Current-Asset-Value | 5.35 | |||||
| Earnings Yield (Greenblatt) % | -3.77 | |||||
| FCF Yield % | 0.82 | |||||
| Forward Rate of Return (Yacktman) % | -34.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hunan Er-Kang Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,511.982 | ||
| EPS (TTM) (Â¥) | -0.106 | ||
| Beta | 0.72 | ||
| Volatility % | 22.64 | ||
| 14-Day RSI | 62.14 | ||
| 14-Day ATR (Â¥) | 0.124246 | ||
| 20-Day SMA (Â¥) | 2.5155 | ||
| 12-1 Month Momentum % | -23.58 | ||
| 52-Week Range (Â¥) | 2.08 - 3.93 | ||
| Shares Outstanding (Mil) | 2,062.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hunan Er-Kang Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hunan Er-Kang Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hunan Er-Kang Pharmaceutical Co Ltd Frequently Asked Questions
What is Hunan Er-Kang Pharmaceutical Co Ltd(SZSE:300267)'s stock price today?
The current price of SZSE:300267 is ¥2.78. The 52 week high of SZSE:300267 is ¥3.93 and 52 week low is ¥2.08.
When is next earnings date of Hunan Er-Kang Pharmaceutical Co Ltd(SZSE:300267)?
The next earnings date of Hunan Er-Kang Pharmaceutical Co Ltd(SZSE:300267) is .
Does Hunan Er-Kang Pharmaceutical Co Ltd(SZSE:300267) pay dividends? If so, how much?
The Dividend Yield %  of Hunan Er-Kang Pharmaceutical Co Ltd(SZSE:300267) is 1.08% (As of Today), Highest Dividend Payout Ratio of Hunan Er-Kang Pharmaceutical Co Ltd(SZSE:300267) was 0.25. The lowest was 0.04. And the median was 0.11. The  Forward Dividend Yield % of Hunan Er-Kang Pharmaceutical Co Ltd(SZSE:300267) is 1.08%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers